Study on Rosuvastatin+Ezetimibe and Rosuvastatin for LDL-C Goal in Patients With Recent Ischemic Stroke

Summary

A randomized clinical trial for the comparison of the efficacy and safety of moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin for target LDL-C goal achievement in patients with recent ischemic stroke

Conditions

• Stroke, Ischemic

Interventions

DRUG

Experimental: Rosuvastatin/Ezetimibe 10

* Rosuvastatin/Ezetimibe 10/10mg * orally administered once daily for 90 days

DRUG

Active Comparator: Rosuvastatin 20mg

* Rosuvastatin 20mg * orally administered once daily for 90 days

Sponsors & Collaborators

• Ewha Womans University Seoul Hospital

  collaborator OTHER

• Severance Hospital

  collaborator OTHER

• Korea University Ansan Hospital

  collaborator OTHER

• Korea University Guro Hospital

  collaborator OTHER

• Myongji Hospital

  collaborator OTHER

• Seoul St. Mary's Hospital

  collaborator OTHER

• Samsung Medical Center

  collaborator OTHER

• Seoul National University Hospital

  collaborator OTHER

• Chung-Ang University Hosptial, Chung-Ang University College of Medicine

  collaborator OTHER

• Hallym University Medical Center

  collaborator OTHER

• Kyunghee University Medical Center

  collaborator OTHER

• Inje University Ilsan Paik Hospital

  collaborator OTHER

• Keun-Sik Hong

  lead OTHER

Principal Investigators

• Keun-Sik Hong, MD., PhD. · Department of Neurology, Inje University Ilsan Paik Hospital

Study Design

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

19 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-09-09

Primary Completion

2021-09-27

Completion

2021-09-27

Countries

• South Korea

Study Locations